A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Trial Profile

A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTA
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 18 Oct 2017 Updated efficacy and safety results (data cut off: 21 Feb, 2017) presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results of a post-hoc analysis assessing the clinical benefit of continuing brigatinib beyond Disease Progression (n=107) presented at the 18th World Conference on Lung Cancer
    • 18 Oct 2017 Results (As of February 21, 2017) assessing the incidence, management, and outcomes of hypertension associated with with brigatinib treatment, presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top